Traders Purchase High Volume of Call Options on Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) saw some unusual options trading activity on Tuesday. Investors purchased 11,070 call options on the stock. This is an increase of approximately 209% compared to the typical volume of 3,588 call options.

Analysts Set New Price Targets

Several equities analysts have weighed in on ROIV shares. TheStreet upgraded shares of Roivant Sciences from a “d” rating to a “c+” rating in a report on Tuesday, February 13th. Truist Financial reiterated a “buy” rating and issued a $23.00 target price on shares of Roivant Sciences in a report on Monday, March 25th. Deutsche Bank Aktiengesellschaft started coverage on shares of Roivant Sciences in a report on Tuesday, December 12th. They issued a “buy” rating and a $14.00 target price on the stock. Bank of America boosted their target price on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Tuesday, January 2nd. Finally, Piper Sandler assumed coverage on shares of Roivant Sciences in a report on Friday, January 5th. They issued an “overweight” rating and a $20.00 price objective on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $16.50.

View Our Latest Stock Analysis on Roivant Sciences

Roivant Sciences Price Performance

Roivant Sciences stock opened at $10.92 on Wednesday. The firm has a market cap of $8.80 billion, a PE ratio of 2.10 and a beta of 1.34. Roivant Sciences has a 52-week low of $6.97 and a 52-week high of $13.24. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06. The company’s 50 day moving average is $10.75 and its two-hundred day moving average is $10.35.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $37.14 million for the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. On average, research analysts expect that Roivant Sciences will post -1.36 EPS for the current fiscal year.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 96,950 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the completion of the sale, the chief operating officer now owns 532,207 shares of the company’s stock, valued at approximately $5,811,700.44. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of Roivant Sciences by 8.1% in the 3rd quarter. FMR LLC now owns 38,910,625 shares of the company’s stock valued at $454,476,000 after purchasing an additional 2,913,491 shares during the last quarter. Morgan Stanley increased its position in shares of Roivant Sciences by 48.7% in the 3rd quarter. Morgan Stanley now owns 19,311,631 shares of the company’s stock valued at $225,560,000 after purchasing an additional 6,324,915 shares during the last quarter. Rubric Capital Management LP increased its position in shares of Roivant Sciences by 81.0% in the 4th quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock valued at $213,370,000 after purchasing an additional 8,500,000 shares during the last quarter. BlackRock Inc. increased its position in shares of Roivant Sciences by 99.5% in the 2nd quarter. BlackRock Inc. now owns 12,372,873 shares of the company’s stock valued at $124,719,000 after purchasing an additional 6,170,264 shares during the last quarter. Finally, State Street Corp increased its position in shares of Roivant Sciences by 18.7% in the 2nd quarter. State Street Corp now owns 9,533,896 shares of the company’s stock valued at $96,102,000 after purchasing an additional 1,500,944 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

About Roivant Sciences

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Read More

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.